{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:28:46Z","timestamp":1793039326486,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s13346-016-0297-8","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T15:24:51Z","timestamp":1461943491000},"page":"498-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability"],"prefix":"10.1007","volume":"6","author":[{"given":"Sanyog","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Appa","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"key":"297_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"297_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"RH Muller","year":"2001","unstructured":"Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3\u201319.","journal-title":"Adv Drug Deliv Rev"},{"key":"297_CR3","first-page":"295","volume":"3","author":"JU Junghanns","year":"2008","unstructured":"Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295\u2013309.","journal-title":"Int J Nanomedicine"},{"key":"297_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2010.03.059","volume":"393","author":"Y Miyako","year":"2010","unstructured":"Miyako Y, Khalef N, Matsuzaki K, Pinal R. Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect. Int J Pharm. 2010;393:48\u201354.","journal-title":"Int J Pharm"},{"key":"297_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2003.09.002","volume":"269","author":"HN Joshi","year":"2004","unstructured":"Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, et al. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm. 2004;269:251\u20138.","journal-title":"Int J Pharm"},{"key":"297_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejpb.2008.05.012","volume":"70","author":"S Ben Zirar","year":"2008","unstructured":"Ben Zirar S, Astier A, Muchow M, Gibaud S. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm. 2008;70:649\u201356.","journal-title":"Eur J Pharm Biopharm"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-3659(01)00299-1","volume":"73","author":"VP Torchilin","year":"2001","unstructured":"Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137\u201372.","journal-title":"J Control Release"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejps.2005.11.012","volume":"28","author":"K Kawakami","year":"2006","unstructured":"Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur J Pharm Sci. 2006;28:7\u201314.","journal-title":"Eur J Pharm Sci"},{"key":"297_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2009.06.001","volume":"73","author":"S Chakraborty","year":"2009","unstructured":"Chakraborty S, Shukla D, Mishra B, Singh S. Lipid\u2014an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73:1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12030-009-9028-2","volume":"5","author":"R Ravichandran","year":"2009","unstructured":"Ravichandran R. Nanotechnology-based drug delivery systems. NanoBiotechnology. 2009;5:17\u201333.","journal-title":"NanoBiotechnology"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","volume":"26","author":"L Willems","year":"2001","unstructured":"Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001;26:159\u201369.","journal-title":"J Clin Pharm Ther"},{"key":"297_CR12","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590\u20138.","journal-title":"Eur J Cancer"},{"key":"297_CR13","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20:1\u201315.","journal-title":"Semin Oncol"},{"key":"297_CR14","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1166\/jbn.2013.1683","volume":"9","author":"S Jain","year":"2013","unstructured":"Jain S, Sharma JM, Agrawal AK, Mahajan RR. Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement. J Biomed Nanotechnol. 2013;9:1862\u201374.","journal-title":"J Biomed Nanotechnol"},{"key":"297_CR15","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2217\/nnm.12.181","volume":"8","author":"S Jain","year":"2013","unstructured":"Jain S, Sharma JM, Jain AK, Mahajan RR. Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine (Lond). 2013;8:1639\u201355.","journal-title":"Nanomedicine (Lond)"},{"key":"297_CR16","unstructured":"Abrahamsson B, Odman J. Candesartan or candesartan cilexetil; improved bioavailability. In.: Google Patents; 2007."},{"key":"297_CR17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1208\/s12249-014-0109-8","volume":"15","author":"K Hoppe","year":"2014","unstructured":"Hoppe K, Sznitowska M. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media. AAPS PharmSciTech. 2014;15:1116\u201325.","journal-title":"AAPS PharmSciTech"},{"key":"297_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejpb.2006.09.012","volume":"65","author":"P Satturwar","year":"2007","unstructured":"Satturwar P, Eddine MN, Ravenelle F, Leroux JC. pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil. Eur J Pharm Biopharm. 2007;65:379\u201387.","journal-title":"Eur J Pharm Biopharm"},{"key":"297_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/s12249-009-9347-6","volume":"11","author":"V Nekkanti","year":"2010","unstructured":"Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech. 2010;11:9\u201317.","journal-title":"AAPS PharmSciTech"},{"key":"297_CR20","doi-asserted-by":"crossref","unstructured":"Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2014;1\u201310.","DOI":"10.3109\/10717544.2014.914986"},{"key":"297_CR21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.nano.2011.08.016","volume":"8","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Gao F, Bu H, Xiao J, Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine. 2012;8:740\u20137.","journal-title":"Nanomedicine"},{"key":"297_CR22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/156720111795767997","volume":"8","author":"SM Shaikh","year":"2011","unstructured":"Shaikh SM, Avachat AM. Enhancement of solubility and permeability of candesartan cilexetil by using different pharmaceutical interventions. Curr Drug Deliv. 2011;8:346\u201353.","journal-title":"Curr Drug Deliv"},{"key":"297_CR23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jsps.2013.03.006","volume":"22","author":"S Gurunath","year":"2014","unstructured":"Gurunath S, Nanjwade BK, Patila PA. Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J. 2014;22:246\u201357.","journal-title":"Saudi Pharm J"},{"key":"297_CR24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3797\/scipharm.1103-17","volume":"79","author":"C Detroja","year":"2011","unstructured":"Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm. 2011;79:635\u201351.","journal-title":"Sci Pharm"},{"key":"297_CR25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/10837450802585278","volume":"14","author":"V Nekkanti","year":"2009","unstructured":"Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol. 2009;14:290\u20138.","journal-title":"Pharm Dev Technol"},{"key":"297_CR26","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.3390\/molecules171113221","volume":"17","author":"E Vaculikova","year":"2012","unstructured":"Vaculikova E, Grunwaldova V, Kral V, Dohnal J, Jampilek J. Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. Molecules. 2012;17:13221\u201334.","journal-title":"Molecules"},{"key":"297_CR27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/jps.21563","volume":"98","author":"B Eerdenbrugh Van","year":"2009","unstructured":"Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, et al. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci. 2009;98:2091\u2013103.","journal-title":"J Pharm Sci"},{"key":"297_CR28","unstructured":"Jain S, Chauhan D, Jain A, Swarnakar N, Harde H, Mahajan R, Kumar D, Valvi P, Das M, Datir S. Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle. Indian Patent Application No 2559\/DEL. 2011 filed on September. 2011;6."},{"key":"297_CR29","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1002\/jps.20913","volume":"96","author":"L Zhou","year":"2007","unstructured":"Zhou L, Yang L, Tilton S, Wang J. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J Pharm Sci. 2007;96:3052\u201371.","journal-title":"J Pharm Sci"},{"key":"297_CR30","doi-asserted-by":"crossref","unstructured":"Yanni S, Thakker DR. Prodrugs: absorption, distribution, metabolism, excretion (ADME) issues. In. Prodrugs: Springer; 2007. p. 1043\u201381.","DOI":"10.1007\/978-0-387-49785-3_29"},{"key":"297_CR31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.2042-7158.2012.01515.x","volume":"64","author":"M Kakran","year":"2012","unstructured":"Kakran M, Shegokar R, Sahoo NG, Gohla S, Li L, M\u00fcller RH. Long\u2010term stability of quercetin nanocrystals prepared by different methods. J Pharm Pharmacol. 2012;64:1394\u2013402.","journal-title":"J Pharm Pharmacol"},{"key":"297_CR32","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1021\/mp100175a","volume":"7","author":"A Dahan","year":"2010","unstructured":"Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernas H, et al. High-permeability criterion for BCS classification: segmental\/pH dependent permeability considerations. Mol Pharm. 2010;7:1827\u201334.","journal-title":"Mol Pharm"},{"key":"297_CR33","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/mp400311j","volume":"10","author":"AK Jain","year":"2013","unstructured":"Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharm. 2013;10:3459\u201374.","journal-title":"Mol Pharm"},{"key":"297_CR34","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/mp400601g","volume":"11","author":"NK Swarnakar","year":"2014","unstructured":"Swarnakar NK, Thanki K, Jain S. Lyotropic liquid crystalline nanoparticles of CoQ10: implication of lipase digestibility on oral bioavailability, in vivo antioxidant activity, and in vitro-in vivo relationships. Mol Pharm. 2014;11:1435\u201349.","journal-title":"Mol Pharm"},{"key":"297_CR35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF02976347","volume":"18","author":"D-M Oh","year":"1995","unstructured":"Oh D-M, Curl RL, Yong C-S, Amidon GL. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch Pharm Res. 1995;18:427\u201333.","journal-title":"Arch Pharm Res"},{"key":"297_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0939-6411(00)00091-6","volume":"50","author":"R Lobenberg","year":"2000","unstructured":"Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3\u201312.","journal-title":"Eur J Pharm Biopharm"},{"key":"297_CR37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s11095-007-9275-7","volume":"24","author":"F Qian","year":"2007","unstructured":"Qian F, Tao J, Desikan S, Hussain M, Smith RL. Mechanistic investigation of Pluronic based nano-crystalline drug-polymer solid dispersions. Pharm Res. 2007;24:1551\u201360.","journal-title":"Pharm Res"},{"key":"297_CR38","doi-asserted-by":"crossref","unstructured":"Mullin JW. Crystallization. Oxford, UK: Butterworth-Heinemann; 2001.","DOI":"10.1016\/B978-075064833-2\/50009-7"},{"key":"297_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3093(99)00420-2","volume":"255","author":"M Weinberg","year":"1999","unstructured":"Weinberg M. A few topics concerning nucleation and crystallization in glasses. J Non-Cryst Solids. 1999;255:1\u201314.","journal-title":"J Non-Cryst Solids"},{"key":"297_CR40","first-page":"125","volume":"8","author":"V Kamalakkannan","year":"2013","unstructured":"Kamalakkannan V, Puratchikody A, Ramanathan L. Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion. Res Pharm Sci. 2013;8:125\u201336.","journal-title":"Res Pharm Sci"},{"key":"297_CR41","doi-asserted-by":"crossref","first-page":"154116","DOI":"10.1063\/1.2996590","volume":"129","author":"A Shchekin","year":"2008","unstructured":"Shchekin A, Rusanov A. Generalization of the Gibbs\u2013Kelvin\u2013K\u00f6hler and Ostwald\u2013Freundlich equations for a liquid film on a soluble nanoparticle. J Chem Phys. 2008;129:154116.","journal-title":"J Chem Phys"},{"key":"297_CR42","unstructured":"Mller RH, Akkar A. Drug nanocrystals of poorly soluble drugs. In. Encyclopedia of nanoscience and nanotechnology. Steveson Ranch, USA: American Scientific Publishers; 2004. p. 627\u201338."},{"key":"297_CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-5173(95)00033-F","volume":"122","author":"M Mosharraf","year":"1995","unstructured":"Mosharraf M, Nystr\u00f6m C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm. 1995;122:35\u201347.","journal-title":"Int J Pharm"},{"key":"297_CR44","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1021\/mp500872g","volume":"12","author":"Y Hasegawa","year":"2015","unstructured":"Hasegawa Y, Higashi K, Yamamoto K, Moribe K. Direct evaluation of molecular states of piroxicam\/poloxamer nanosuspension by suspended-state NMR and Raman spectroscopies. Mol Pharm. 2015;12:1564\u201372.","journal-title":"Mol Pharm"},{"key":"297_CR45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/03639045.2011.640331","volume":"38","author":"CC Wei","year":"2012","unstructured":"Wei CC, Ge ZQ. Influence of electrolyte and poloxamer 188 on the aggregation kinetics of solid lipid nanoparticles (SLNs). Drug Dev Ind Pharm. 2012;38:1084\u20139.","journal-title":"Drug Dev Ind Pharm"},{"key":"297_CR46","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","volume":"175","author":"P Artursson","year":"1991","unstructured":"Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175:880\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"297_CR47","first-page":"75","volume":"7","author":"D Sun","year":"2004","unstructured":"Sun D, Yu LX, Hussain MA, Wall DA, Smith RL, Amidon GL. In vitro testing of drug absorption for drug \u2018developability\u2019 assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel. 2004;7:75\u201385.","journal-title":"Curr Opin Drug Discov Devel"},{"key":"297_CR48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1773-2247(06)50084-X","volume":"16","author":"J Hecq","year":"2006","unstructured":"Hecq J, Nollevaux G, Deleers M, Fanara D, Vranckx H, Peulen O, et al. Nifedipine nanocrystals: pharmacokinetic evaluation in the rat and permeability studies in Caco-2\/HT29-5M21 (co)-cultures. J Drug Delivery Sci Technol. 2006;16:437\u201342.","journal-title":"J Drug Delivery Sci Technol"},{"key":"297_CR49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajps.2014.08.005","volume":"10","author":"VB Junyaprasert","year":"2015","unstructured":"Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10:13\u201323.","journal-title":"Asian J Pharm Sci"},{"key":"297_CR50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijpharm.2014.12.003","volume":"478","author":"BK Ahuja","year":"2015","unstructured":"Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2015;478:540\u201352.","journal-title":"Int J Pharm"},{"key":"297_CR51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/138920010791110836","volume":"11","author":"Z Cai","year":"2010","unstructured":"Cai Z, Wang Y, Zhu LJ, Liu ZQ. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab. 2010;11:197\u2013207.","journal-title":"Curr Drug Metab"},{"key":"297_CR52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","volume":"170","author":"K Thanki","year":"2013","unstructured":"Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170:15\u201340.","journal-title":"J Control Release"},{"key":"297_CR53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejpb.2012.09.014","volume":"83","author":"Z Wei","year":"2013","unstructured":"Wei Z, Yuan S, Hao J, Fang X. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123\/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm. 2013;83:266\u201374.","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-016-0297-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-016-0297-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-016-0297-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T04:30:01Z","timestamp":1567830601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-016-0297-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,29]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s13346-016-0297-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,29]]}}}